plitidepsin: Clinical Trials

6 terminated. 6 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Terminated 6
Phase 1	1	Terminated 1

Follow plitidepsin: new trials by email Literature Review of plitidepsin trials Research Report on plitidepsin

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) Plitidepsin - COVID-19	Phase 2	Terminated	PharmaMar	37	2023-04-19	2024-12-02
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide plitidepsin, Bortezomib, Dexamethasone - Multiple Myeloma	Phase 2	Terminated	PharmaMar	10	2017-05-08	2020-12-02
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma plitidepsin - Lymphoma	Phase 2	Terminated	PharmaMar	14	2016-10-25	2020-10-14
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial plitidepsin - Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma	Phase 2	Terminated	Institut Bergonié	24	2012-02-01	2021-01-25
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia Plitidepsin plus Cytarabine - Relapsed/Refractory Leukemia	Phase 1 / Phase 2	Terminated	PharmaMar	3	2007-11-01	2018-11-09
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer Aplidin (plitidepsin) - Prostate Cancer	Phase 2	Terminated	PharmaMar	8	2005-02-01	2020-11-24

Conditions studied

Neoplasms (2)  ·  COVID-19 (1)  ·  Leukemia (1)  ·  Liposarcoma (1)  ·  Lymphoma (1)  ·  Multiple Myeloma (1)  ·  Neoplasm Metastasis (1)  ·  Prostatic Neoplasms (1)  ·  Recurrence (1)

Sponsors

PharmaMar (5)  ·  Institut Bergonié (1)

Countries

France (3)  ·  Italy (3)  ·  Spain (3)  ·  United States (3)  ·  Belgium (1)  ·  Czechia (1)  ·  Georgia (1)  ·  Greece (1)  ·  Hungary (1)  ·  Israel (1)  ·  Poland (1)  ·  Portugal (1)  ·  United Kingdom (1)

Top investigators

Antoine Italiano, MD (1)  ·  Celestia Higano, M.D. (1)  ·  Maha Hussain, M.D. (1)  ·  Mecide Gharibo, M.D. (1)

Results publications

PMID 26041763, PMID 39182994